Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;153(4):458-65.
doi: 10.1016/j.jpeds.2008.05.062.

Dyslipidemia in youth with diabetes: to treat or not to treat?

David M Maahs  1 , R Paul Wadwa, Franziska Bishop, Stephen R Daniels, Marian Rewers, Georgeanna J Klingensmith
Affiliations
Review

Dyslipidemia in youth with diabetes: to treat or not to treat?

David M Maahs et al. J Pediatr. 2008 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. AHA Guidelines for Risk Stratification and Treatment in Youth with Diabetes
[adapted from Kavey(29)]
Figure 2A and 2B
Figure 2A and 2B. Hypothetical Relationship of LDL-c, LDL-c-lowering and Future CVD in Youth with Diabetes
Youth with diabetes are at increased risk of future cardiovascular disease. The question remains as to the timing of pharmacologic intervention. Numerous factors influence this decision including background risk of CVD for youth with diabetes, safety of pharmacologic agents, degree of long-term benefit to be gained from intervention, etc. Currently, data are insufficient to determine the degree of benefit to be obtained from early intervention on CVD risk factors in youth with diabetes in reducing this cumulative area under the curve of CVD risk factors. Figure 2A represents possible long-term risk reduction assuming high background CVD risk and benefit from LDL-c lowering, and Figure 2B represents lower background CVD risk and less benefit from LDL-c lowering.
Figure 2A and 2B
Figure 2A and 2B. Hypothetical Relationship of LDL-c, LDL-c-lowering and Future CVD in Youth with Diabetes
Youth with diabetes are at increased risk of future cardiovascular disease. The question remains as to the timing of pharmacologic intervention. Numerous factors influence this decision including background risk of CVD for youth with diabetes, safety of pharmacologic agents, degree of long-term benefit to be gained from intervention, etc. Currently, data are insufficient to determine the degree of benefit to be obtained from early intervention on CVD risk factors in youth with diabetes in reducing this cumulative area under the curve of CVD risk factors. Figure 2A represents possible long-term risk reduction assuming high background CVD risk and benefit from LDL-c lowering, and Figure 2B represents lower background CVD risk and less benefit from LDL-c lowering.
See this image and copyright information in PMC

Comment in

References

    1. Liese AD, D'Agostino RB, Jr., Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Peds. 2006;118:1510–1518. - PubMed
    1. EURODIAB ACE Study Group Variation and trends in incidence of childhood diabetes in Europe. Lancet. 2000;355:873–876. - PubMed
    1. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700. - PubMed
    1. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith G, Bloch C, et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diab Care. 2007;30:503–509. - PubMed
    1. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296:421–426. - PubMed

Publication types

MeSH terms